KyungDong Pharm home
Prescription Medicines

Atrovan Tab.

Product Category
Hyperlipidemia treatment
Active Ingredients
Atorvastatin Calcium Trihydrate
Appearance
A white, oval, film-coated tablet.
Reimbursement Code
648101430
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Atorvastatin calcium trihydrate (USP/in-house specification) ---------- 10.85mg (10mg as atorvastatin)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: microcrystalline cellulose, titanium oxide, magnesium stearate, carnauba lead, croscarmellose sodium, calcium carbonate, polysorbate 80,
Polyethylene glycol 6000, hydroxypropyl cellulose, hypromellose 2910

2. Efficacy/Effectiveness
1. Reduces the risk of the following cardiovascular diseases:
1) There is no clinical evidence for coronary heart disease, but multiple risk factors for coronary heart disease (age 55 or older, smoking, high blood pressure, low HDL-cholesterol level)
or family history of premature coronary heart disease, etc.)
(1) Reduced risk of myocardial infarction
(2) Reduced risk for stroke
(3) Reduction of risk for revascularization and chronic stable angina
2) Type 2 diabetes patients with no clinical evidence of coronary heart disease but with multiple risk factors for coronary heart disease (retinopathy, albuminuria, smoking, or hypertension, etc.)
(1) Reduced risk of myocardial infarction
(2) Reduced risk for stroke
3) Adult patients with clinical evidence of coronary heart disease
(1) Reduced risk of non-fatal myocardial infarction
(2) reduced risk for fatal and nonfatal stroke;
(3) Reduced risk of revascularization
(4) Reduced risk of hospitalization due to congestive heart failure
(5) Reduced risk for angina pectoris
2. Hyperlipidemia
1) Elevated total cholesterol in patients with primary hypercholesterolemia (heterozygous familial and non-familial types) and mixed dyslipidemia (Fredrickson Type IIa and IIb);
Dietary supplement that reduces LDL-cholesterol, apo-B protein, and triglyceride levels and increases HDL-cholesterol levels.
2) Primary dysbetalipoproteinemia (Fredrickson Type III) that does not respond appropriately to diet therapy
3) Dietary supplement for patients with elevated serum triglycerides (Fredrickson Type IV)
4) To reduce total cholesterol and LDL-cholesterol levels in patients with homozygous familial hypercholesterolemia, use other lipid-lowering drugs (e.g., LDL-apheresis)
When concurrent use or treatment with other lipid-lowering drugs is not possible
3. Pediatric patients aged 10 to 17 years (for women, patients after menarche) with heterozygous familial hypercholesterolemia who still meet the criteria below despite dietary treatment.
Dietary supplement to reduce total cholesterol, LDL-cholesterol, and apo-B protein levels
A. LDL-cholesterol is still above 190 mg/dL (≥ 190 mg/dL)
B. If LDL-cholesterol is still above 160 mg/dL (≥ 160 mg/dL) and there is a family history of premature cardiovascular disease or two or more other
If you have risk factors for cardiovascular disease

3. Usage/Dosage
Patients before and while taking atorvastatin must eat a standard cholesterol-lowering diet, and the drug can be administered at any time of the day, regardless of food.
1. Hyperlipidemia:
The recommended initial dose is 10 mg of atorvastatin once daily, but for patients requiring greater LDL-cholesterol level reduction, 20 mg or 40 mg once daily (45%)
(Limited to cases where a reduction in LDL-cholesterol level above is required.) can be started. This drug is administered once a day in a dosage range of 10 mg to 80 mg.
The initial dose and maintenance dose of this drug should be individualized according to the patient's characteristics, taking into account treatment goals and responses. After starting administration and/or dose titration, lipid levels should be reduced within 2 to 4 weeks.
should be analyzed and the capacity adjusted accordingly.
Since the goal of treatment is to lower LDL-cholesterol levels, it is recommended to use LDL-cholesterol levels when starting treatment and evaluating treatment response.
However, when LDL-cholesterol levels are not available, total cholesterol levels are used to monitor treatment response.
• Patients with homozygous familial hypercholesterolemia:
The dosage of this drug is 10 mg to 80 mg once a day. This drug can be used in combination with other lipid-lowering treatments (e.g., LDL apheresis) or when such lipid-lowering treatments are not possible.
Administer.
2. Pediatric patients (10 to 17 years old) with heterozygous familial hypercholesterolemia:
The recommended initial dose of this drug is 10 mg per day, and the maximum recommended dose is 20 mg per day. (There is no clinical data on doses higher than 20 mg in pediatric patients.)
The administered dose is appropriately increased or decreased depending on the treatment goal recommended for each patient. The dosage should be adjusted at intervals of 4 weeks or more.
• Patients with renal impairment: There is no need to adjust the dose because renal disease does not affect the plasma concentration or LDL-cholesterol lowering effect of atorvastatin.
• Elderly: Efficacy and safety for elderly patients over 70 years of age are similar to those for adult patients.

4. Precautions for use
1. Warning
Discontinue atorvastatin if markedly elevated creatine kinase (CK) levels occur or myopathy is diagnosed or suspected. Atorvastatin should also be temporarily withheld or discontinued in patients with acute, serious conditions suggestive of myopathy or risk factors for renal failure secondary to rhabdomyolysis, such as severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine or electrolyte disorders, or uncontrolled seizures. See “General Precautions: Myopathy/Rhabdomyolysis.”

2. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug or its components (anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis)
2) Patients with active liver disease or patients whose serum transaminase level is more than 3 times the upper limit of normal
3) Patients with muscle disease
4) Pregnant women or women who may be pregnant and lactating women
5) Children under 10 years of age
6) Patients receiving glecaprevir and pibrentasvir
7) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
8) Patients with acute liver failure or decompensated cirrhosis

3. Administer with caution to the following patients.
1) Patients with a history of alcoholism or liver disease (see ‘Adverse Reactions’ section)
2) For patients with the following predisposition to rhabdomyolysis, the CK level should be measured before starting administration and administration should be done with caution.
(1) Patients with a history of impaired renal function or renal dysfunction
(2) Patients with hypothyroidism
(3) Patients with a personal or family history of hereditary muscle abnormalities
(4) Patients with a history of muscle toxicity when using statins or fibrates
(5) If you have a history of liver disease or consume a significant amount of alcohol
(6) Elderly patients over 70 years old with a predisposition to rhabdomyolysis
3) Patients with severe muscle atony or ocular muscle atony (cases of recurrence when administered the same or different types of statin drugs have been reported).

4. Adverse reactions
1) Atorvastatin is generally well tolerated. Adverse reactions were generally mild and transient. Treatment discontinuation during clinical trials due to adverse reactions related to this drug occurred in less than 2% of patients. In a placebo-controlled clinical trial for atorvastatin, 16,066 patients (8,755 in the atorvastatin group vs. 7,311 in the placebo group) received the drug for a median period of 53 weeks, and 4.0% of the placebo group and 5.2% of the atorvastatin group discontinued treatment due to adverse reactions.
2) Based on clinical trials and post-marketing surveillance, the adverse reactions of this drug are as follows. The frequency of adverse reactions is as follows. ; Very often (≥ 1/10), often (≥ 1/100, <1/10), sometimes (≥ 1/1,000, <1/100), rarely (≥ 1/10,000, <1/1,000), very rarely (<1/10,000)
(1) Whole body: Sometimes lethargy, malaise, chest pain, peripheral edema, fatigue, fever
(2) Infection: Frequent nasopharyngitis
(3) Metabolic system: frequent hyperglycemia, occasional hypoglycemia, weight gain, loss of appetite
(4) Digestive system: frequent constipation, abdominal bloating, indigestion, nausea, diarrhea, occasional abdominal pain, vomiting, burping, pancreatitis.
(5) Respiratory system: frequent pharynx and larynx pain, nosebleeds
(6) Mental system: Sometimes insomnia, nightmares
(7) Nervous system: frequent headaches, occasional dizziness, paresthesia, hypoesthesia, dysgeusia, memory loss, rarely peripheral neuropathy.
(8) Musculoskeletal system and connective tissue: frequent muscle pain, joint pain, limb pain, musculoskeletal pain, muscle cramps, joint swelling, back pain, sometimes neck pain, muscle fatigue, complications due to rupture; Rarely myopathy, myositis, rhabdomyolysis, tendon disorder, muscle rupture, very rarely lupus-like syndrome, frequency unknown - immune-mediated necrotizing myopathy.
(9) Blood and lymphatic system: rarely thrombocytopenia
(10) Vascular system: Vasculitis
(11) Immune system: frequent allergic reactions, very rare anaphylaxis
(12) Liver/biliary system: Sometimes hepatitis, rarely cholestasis, very rarely liver failure
(13) Eyes: Sometimes blurred vision, rarely visual impairment
(14) Ears: Sometimes tinnitus, very rarely hearing loss.
(15) Skin and subcutaneous tissue: Occasionally urticaria, skin rash, itching, hair loss, angioedema, rarely angioneurotic edema, bullous dermatitis including erythema multiforme, mucocutaneous ophthalmic syndrome (Stevenson-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), lichenoid drug reaction
(16) Reproductive system: Gynecomastia, very rare.
(17) Tests: Frequently abnormal liver function tests, increased CK in blood, sometimes positive leukocytes in urine
3) During the atorvastatin placebo-controlled clinical study, the following additional adverse reactions occurred. Not all adverse reactions described below are causally related to atorvastatin.
(1) Mental world: nightmare
(2) Eyes: Blurred vision
(3) Ears: Tinnitus
(4) Digestive system: Vomiting, abdominal abnormalities, hepatitis, pancreatitis, cholestasis, cholestatic jaundice, liver function test abnormalities (elevated serum ALT level), gastroenteritis, enteritis, dry mouth, rectal bleeding, esophagitis, burping, glossitis, oral ulcer, stomatitis, gallbladder pain, cheilitis, gastric/duodenal ulcer, dysphagia, melena, gingival bleeding, second-grade post-excretion (excretion) pain that lingers behind)
(5) Respiratory system: bronchitis, rhinitis, pneumonia, difficulty breathing, asthma, nosebleeds
(6) Nervous system: sensory abnormalities (paresthesia), peripheral neuropathy, dizziness, light sensitivity, drowsiness, forgetfulness, abnormal dreams, decreased libido, emotional anxiety, motor incoordination, torticollis, facial paralysis, hyperkinesis, depression, hypertonia.
(7) Musculoskeletal system and connective tissue: muscle cramps, muscle fatigue, myositis, muscle disease, arthritis, bursitis, tenosynovitis, myasthenia gravis, neck pain, tendon contracture, increased CK, increased blood myoglobin.
(8) Skin and subcutaneous tissue: itching, rash, alopecia, contact dermatitis, dry skin, sweating, acne, urticaria, eczema, seborrhea, skin ulcers
(9) Urogenital system: impotence, urinary tract infection, frequent urination, cystitis, hematuria, dysuria, kidney stones, nocturia, epididymitis, breast fibroid cyst, vaginal bleeding, albuminuria, breast hypertrophy, cervical discharge, nephritis, urinary incontinence, urinary retention, urgency, abnormal ejaculation, uterine bleeding, pigmented urine.
(10) Metabolic and nutritional disorders: hypoglycemia, hyperglycemia, anorexia, increased appetite
(11) Systemic abnormalities and administration site abnormalities: malaise, angioneurotic edema, chest pain, angina, facial edema, fever, neck stiffness, general edema
(12) Special senses: amblyopia, tinnitus, dry eyes, refractive error, ocular hemorrhage, hearing loss, glaucoma, sense of smell, loss of taste, perversion of taste.
(13) Blood and lymphatic system: thrombocytopenia, leukopenia, anemia
(14) Endocrine system: decreased testosterone, increased corinesterase, increased TSH, increased ACTH, decreased aldosterone, gynecomastia.
(15) Kidney: Increased potassium, increased BUN
(16) Others: cerebral infarction, palpitations, tachycardia
(17) Test: positive white blood cells in urine
4) Pediatric patients (10 to 17 years old) (corresponding to atorvastatin tablets 10 and 20 mg)
The adverse reaction profile seen in a 6-month clinical trial in pediatric patients aged 10 to 17 years with heterozygous familial hyperlipidemia was generally similar to that seen in the placebo group. Regardless of the causal relationship with the drug, the most common adverse reaction in both groups was infection.
5) In clinical studies, an increase in plasma CK levels (more than 3 times the normal range) occurred in 3.1% of cases with other HMG-CoA reductase inhibitors, compared to 2.5% with atorvastatin. Cases showing levels more than 10 times the upper limit of normal range occurred in 0.4% of patients receiving atorvastatin. Of these patients, 0.1% had muscle pain, tenderness, or weakness.
6) The results of the usage results survey conducted in Korea for 6 years after marketing are as follows.
(1) General use results survey: As a result of a post-marketing survey conducted on 11,535 people, the frequency of adverse reactions was reported to be 1.78% (205 cases/11,535 cases) regardless of causal relationship. Among these, new adverse reactions that did not appear in pre-marketing clinical trials were reported: 7 cases of hypertriglyceridemia, 4 cases of facial flushing, 3 cases each of increased specific protein content and hyperuricemia, and 1 case of gingival thickening.
(2) Long-term use results survey: As a result of a long-term post-marketing survey conducted on 2,625 people who took this drug for more than 12 weeks, the frequency of adverse reactions was reported to be 3.70% (97 cases/2,625 cases) regardless of causal relationship. Among these, seven cases of hyperuricemia, facial flushing, hypothermia, and increased non-protein content were reported as new adverse reactions that did not appear in pre-market clinical trials.
7) The following adverse reactions have been reported in relation to some statin drugs.
(1) Mental nervous system: sleep disorders (including insomnia and nightmares), memory loss, depression
(2) Respiratory system: exceptional cases such as interstitial lung disease, especially during long-term administration
(3) Urogenital system: sexual dysfunction
(4) Endocrine system: Diabetes: The frequency varies depending on the presence of risk factors. (Fasting blood sugar 5.6~6.9 mmol/L, BMI>30kg/m2, increased triglyceride level, high blood pressure)
(5) Post-marketing cognitive impairment has been rarely reported in association with statin use. (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) Such cognitive impairment has been reported with all statin drugs. These reports are generally not serious and reversible after discontinuation of drug use, but there is variation in the time of symptom onset (1 day to several years) and symptom improvement (median 3 weeks).
(6) The induction or worsening of severe muscle atony or ocular muscle atony has been reported in connection with the administration of statin drugs.
8) As a result of analyzing domestic voluntary adverse event reporting data (1989-2013), the following adverse events were reported in statistically significantly higher numbers compared to adverse events occurring from other drugs for which adverse events were reported. However, this does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
- Increased AST

5. General precautions
1) Gender: The concentration of atorvastatin in women (Cmax is approximately 20% higher and AUC is approximately 10% lower) is different from that in men. These differences were not clinically significant, and the effects on lipids were not clinically different between men and women.
2) Renal failure: Renal disease did not affect the plasma concentration or LDL-cholesterol lowering effect of atorvastatin.
3) Liver failure: The plasma concentration of atorvastatin increased significantly (Cmax about 16 times, AUC about 11 times) in patients with chronic alcoholic liver disease (Child-Pugh Class B).
4) Hepatitis: Hepatitis such as fulminant hepatitis may occur after taking this drug. If symptoms such as nausea, vomiting, or malaise occur, stop taking the drug and notify your doctor.
5) Women of childbearing potential: Women of childbearing potential receiving this drug must use appropriate contraception while taking this drug.
6) Interstitial lung disease: Unusual cases such as interstitial lung disease have been reported with some statin drugs, especially during long-term administration. Presenting symptoms may include difficulty breathing, non-productive coughing and general deterioration of health (fatigue, weight loss and fever). If a patient is suspected of developing interstitial lung disease, statin drug treatment should be discontinued.
7) Myopathy/rhabdomyolysis: Rhabdomyolysis accompanied by acute renal failure secondary to myoglobinuria has been rarely reported with this drug and other drugs in this class. A history of renal dysfunction may be a risk factor for developing rhabdomyolysis. These patients may benefit from close monitoring of skeletal muscle effects.
Like other statins, atorvastatin may occasionally cause myopathy, defined as muscle pain or weakness combined with an increase in CK greater than 10 times the upper limit of normal. High-dose coadministration of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, elbasvir, grazoprevir, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis.
Immune-mediated necrotizing myopathy, an autoimmune myopathy associated with statin use, has been rarely reported, including cases of recurrence when the same or different statins were administered. Immune-mediated necrotizing myopathy occurs with proximal muscle weakness and increased CK in the blood, and the symptoms persist even after discontinuation of statin administration. If immune-mediated necrotizing myopathy is suspected, administration of this drug should be discontinued. In addition, the patient is positive for anti-HMG CoA reductase antibody, and muscle biopsy shows necrotizing myopathy without significant infection, and symptoms improve upon administration of immunosuppressants.
Myopathy should be considered in patients with diffuse muscle pain, muscle tension, muscle weakness, and/or significant CK elevation. In particular, patients who experience unexplained muscle pain, muscle tension, or muscle weakness accompanied by lethargy or fever should be instructed to report it immediately.
The risk of myopathy during drug therapy in this class is increased with cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, telaprevir, boceprevir, combination therapy with HIV protease inhibitors (saquinavir and ritonavir, lopinavir and ritonavir, tipranavir and ritonavir, darunavir and ritonavir, fosamprenavir, It increases when administered concurrently with fosamprenavir and ritonavir), nicotinic acid, and azole antifungal agents. Physicians considering co-administration of fibric acid derivatives or lipid-altering doses of nicotinic acid and atorvastatin should carefully consider whether the therapeutic benefits outweigh the risks, carefully monitor signs and symptoms related to muscle pain, muscle tension, or muscle weakness (especially in the first month of administration and during the appropriate period for increasing the dose of one of the two drugs), and should carefully monitor low-dose atorvastatin. Reduction of starting and maintenance doses should be considered. Atorvastatin and fusidic acid (oral medication) should not be administered together. Periodic measurement of CK levels should be considered, but there is no certainty that monitoring will prevent the development of serious myopathy.
Cases of myopathy, including rhabdomyolysis, have been reported with concomitant use of this medicine and colchicine. Use caution when prescribing them together.
Myopathy and/or rhabdomyolysis have been reported when daptomycin and HMG-CoA reductase inhibitors were coadministered. Daptomycin and HMG-CoA reductase inhibitors may cause myopathy and/or rhabdomyolysis when administered alone, so caution should be exercised when coadministered. In patients receiving daptomycin, temporary discontinuation of daptomycin should be considered.
8) Abnormal liver function: Like other lipid-lowering treatments, statins are associated with biochemical abnormalities in liver function. In clinical trials, a continuous increase in serum aminotransferase levels (an increase of more than 3 times the upper limit of normal (ULN) more than twice) was observed in 0.7% of patients treated with atorvastatin (0.2% in the 10 mg group, 0.2% in the 20 mg group, 0.6% in the 40 mg group, and 2.3% in the 80 mg group).
After administering this drug, adverse reactions such as abnormal liver function, jaundice, fulminant hepatitis, and hepatitis may occur. Therefore, if any abnormalities are recognized through sufficient observation, such as conducting regular tests, discontinue administration and take appropriate measures.
A liver function test must be performed before starting treatment, and thereafter, in patients who show clinical signs of liver damage, the liver function test must be repeated. Fatal and non-fatal liver failure have been rarely reported in patients taking statins in post-marketing studies. If severe liver damage and/or hyperbilirubinemia or jaundice appear along with clinical symptoms during treatment with this drug, discontinue treatment immediately. This drug should not be administered again unless an alternative etiology is found.
Atorvastatin should be administered cautiously to alcohol abusers (overdosers) or people with a history of liver disease. Atorvastatin should not be administered to patients with active liver disease or persistent unexplained elevations in serum transaminase levels.
9) Endocrine function: An increase in HbA1c and fasting serum glucose levels has been reported with HMC-CoA reductase inhibitors, including this drug. However, the benefit of reducing vascular risk due to administration of statins outweighs the risk of hyperglycemia.
10) Hemorrhagic stroke: In a post-hoc analysis of a clinical trial in which 80 mg of atorvastatin was administered as a starting dose to 4,731 patients who had no history of coronary heart disease but had experienced a stroke or transient ischemic attack within the past 6 months, it was reported that the occurrence of hemorrhagic stroke was higher in the atorvastatin 80 mg group compared to the placebo group (Atorvastatin 55 people in the treatment group vs. 33 people in the placebo group). This risk appears to have increased in patients who had already had a hemorrhagic stroke at the start of the clinical trial (7 patients in the atorvastatin group vs. 2 in the placebo group). However, patients receiving 80 mg of atorvastatin had a lower incidence of total stroke (265 vs. 311) and coronary heart disease (123 vs. 204) than the placebo group. Consider the risk/benefit of using this drug 80 mg in patients who have recently had a hemorrhagic stroke.
11) CK level measurement: CK should not be measured after intense exercise or when other factors that increase CK level exist. If CK levels are significantly elevated from baseline, these levels should be remeasured in 5 to 7 days to confirm results.
12) If you experience muscle pain, tenderness, or muscle weakness, especially accompanied by malaise or fever, during treatment with this medicine, you should immediately notify your doctor.
If these symptoms appear while taking this medicine, CK levels should be measured. If this level is significantly elevated (>5 times the upper limit of normal (ULN)), treatment should be discontinued.
If muscle symptoms are severe and cause daily discomfort, discontinuation of treatment should be considered even if the CK level is five times the upper limit of normal.
If symptoms resolve and CK levels return to normal, re-administration of this drug or introduction of an alternative statin should be considered with close monitoring.
This drug should be discontinued if clinically significant elevations in CK levels are noted or if rhabdomyolysis is diagnosed or suspected.
13) Mucocutaneous ocular syndrome (Stevenson-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), erythema multiforme: There are reports of blistering rashes such as mucocutaneous ocular syndrome (Stevenson-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), and erythema multiforme. If these symptoms appear, discontinue administration.
14) Diabetes: Some evidence has been presented that hyperglycemia, which requires appropriate diabetes treatment, may occur in some patients at high risk of developing diabetes in the future. However, the vascular risk reduction effect of statins exceeds these risks and therefore cannot be a reason to discontinue statin treatment. Patients at risk (fasting blood sugar 5.6-6.9 mmol/L, BMI > 30kg/m2, elevated triglyceride level, hypertension) should undergo clinical and laboratory monitoring according to treatment guidelines.
15) In rare cases, statin drugs may cause or worsen severe muscle atony or ocular muscle atony. This drug should be used with caution in patients with these conditions. Administration should be discontinued if severe muscle atony or ocular muscle atony occurs or worsens.

6. Interaction
1) Strong CYP3A4 inhibitor: This drug is metabolized by CYP3A4. Coadministration of this drug with strong CYP3A4 inhibitors may increase plasma concentrations of atorvastatin. The extent of interaction and potentiation of effect depend on the fluctuating effect on CYP3A4.
(1) Erythromycin, clarithromycin: In healthy subjects, atorvastatin plasma concentration increased when atorvastatin was coadministered with erythromycin (500 mg, 4 times a day) or clarithromycin (500 mg, 2 times a day, 1 time), known CYP3A4 inhibitors. Therefore, caution should be exercised when administering more than 20 mg of this drug to patients taking clarithromycin.
(2) Combination use with protease inhibitors: Atorvastatin AUC was significantly increased by co-administration of this drug with several HIV protease inhibitors, similar to the hepatitis C protease inhibitor telaprevir, compared to administration of this drug alone. Therefore, the combined use of this drug should be avoided in patients receiving the HIV protease inhibitor tipranovir and ritonavir combination therapy or the hepatitis C protease inhibitor telaprevir. Caution should be exercised when prescribing this drug to patients receiving the HIV protease inhibitor lopinavir and ritonavir combination therapy and the lowest dose should be used. In patients receiving the HIV protease inhibitor saquinavir and ritonavir combination therapy, darunavir and ritonavir combination therapy, fosamprenavir, or fosamprenavir and ritonavir combination therapy, the dose of this drug should not exceed 20 mg and should be used with caution.
In HIV patients receiving nelfinavir, treatment with nelfinavir is limited to 40 mg, and appropriate clinical evaluation is recommended to ensure that the minimum required dose of nelfinavir is applied.
When boceprevir 800mg, 3 times a day and 40mg of this drug, once a day were co-administered for 7 days, the AUC and Cmax of this drug increased by 2.30-fold and 2.66-fold, respectively. Patients receiving boceprevir should not exceed 40 mg per day.
(3) Itraconazole: Atorvastatin AUC was significantly increased by co-administration of 200 mg of itraconazole and 40 mg of this drug. Therefore, caution should be exercised when administering more than 20 mg of this drug to patients receiving itraconazole.
2) Since this drug is a substrate of P-glycoprotein, co-administration with a P-glycoprotein inhibitor (e.g. cyclosporine) increases the bioavailability of this drug, increasing the risk of adverse reactions such as muscle disease.
3) When this drug is administered with CYP3A4 inhibitors (cyclosporine, macrolide antibiotics, and azole antifungals), the plasma concentration of this drug may increase, so it should be administered with caution.
4) Rifampicin or other CYP3A4 inducers: Co-administration of this drug with CYP3A4 inducers (e.g. efavirenz, rifampicin) may decrease the blood concentration of atorvastatin. Because of the dual interaction mechanism of rifampicin (CYP3A4 induction and hepatocyte uptake transporter OATP1B1 inhibition), simultaneous administration of atorvastatin and rifampicin is recommended. If atorvastatin is administered late after rifampicin administration, the blood concentration of atorvastatin significantly decreases.
5) No clinically significant interactions were observed in clinical studies using this drug in combination with antihypertensive agents, hypoglycemic agents, or estrogen replacement therapy. Interactions with all unusual agents have not yet been studied.
6) Drug transporter inhibitor: Atorvastatin and its metabolites are substrates of the OATP1B1 transporter. OATP1B1 inhibitors (e.g., cyclosporine) may increase the bioavailability of atorvastatin. Co-administration of atorvastatin 10 mg and cyclosporine 5.2 mg/kg/day increased the AUC of atorvastatin by 8.7-fold. When atorvastatin is administered in combination with cyclosporine, the administered dose of atorvastatin should not exceed 10 mg.
7) Breast cancer resistance protein (BCRP) inhibitor: When administered in combination with a BCRP inhibitor (e.g., elbasvir, grazoprevir), the plasma concentration of atorvastatin may increase, which may increase the risk of myopathy, so dose adjustment of atorvastatin may be necessary. When atorvastatin is administered in combination with elbasvir and grazoprevir, the plasma concentration of atorvastatin increases by 1.9-fold. Therefore, for patients receiving elbasvir or grazoprevir-containing preparations together with this drug, the dose of atorvastatin should not exceed 20 mg per day (see ‘General Precautions’).
8) Digoxin: When atorvastatin 10 mg and digoxin are administered in multiple doses, the steady-state plasma concentration of digoxin is not affected. However, after coadministering 80 mg of atorvastatin with digoxin in multiple doses, the steady-state plasma digoxin concentration increased by approximately 20%. Patients receiving digoxin should be appropriately monitored.
9) Oral contraceptives: When this drug was co-administered with oral contraceptives containing norethisterone and ethinyl estradiol, the AUC of norethisterone and ethinyl estradiol increased by approximately 30% and 20%, respectively. Therefore, women receiving atorvastatin should take this into consideration when choosing an oral contraceptive.
10) Colestipol: When coadministered with colestipol, the plasma concentration of atorvastatin decreased by about 25%. However, the LDL-cholesterol lowering effect was greater when atorvastatin and colestipol were administered together than when these drugs were administered alone.
11) Antacid: When administered in combination with this drug and an oral antacid suspension containing magnesium hydroxide and aluminum hydroxide, the plasma concentration of atorvastatin decreased by approximately 35%. However, there was no effect on the reduction of LDL-cholesterol.
12) Warfarin: Studies were conducted on the interaction between atorvastatin and warfarin. However, there was no clinically significant interaction.
13) Antipyrine: Coadministration of multiple doses of this drug and antipyrine has little effect on the clearance of antipyrine, so interactions with drugs metabolized via the same CYP-450 isoenzyme are not expected.
14) Cimetidine: No interaction was confirmed in the interaction study between cimetidine and this drug.
15) Azithromycin: Co-administration of atorvastatin (10 mg once daily) and azithromycin (500 mg once daily) did not affect the plasma concentration of atorvastatin.
16) Amlodipine: In a drug-drug interaction test on healthy volunteers, when 80 mg of atorvastatin was administered in combination with 10 mg of amlodipine, the exposure to atorvastatin increased by 18%, but the result was not clinically meaningful.
17) Terfenadine: When atorvastatin and terfenadine were administered together, there was no clinically significant effect on the pharmacokinetics of terfenadine.
18) Diltiazem: When atorvastatin (40 mg) and diltiazem (240 mg) were administered together, the blood concentration of atorvastatin was higher.
19) Grapefruit juice: Grapefruit juice contains one or more ingredients that inhibit CYP3A4, which can increase the blood concentration of atorvastatin if grapefruit juice is consumed excessively (more than 1.2 L per day).
20) Fusidic acid (oral): Although no tests have been conducted on drug interactions between atorvastatin and fusidic acid, severe muscle abnormalities such as rhabdomyolysis have been reported in post-marketing experience with co-administration of these two drugs. These patients should be closely monitored, and atorvastatin treatment should be temporarily discontinued.
21) Nicotinic acid: When used together with nicotinic acid, the risk of skeletal muscle effects may increase, so a dose reduction of this drug should be considered.
22) Colchicine: Although no tests have been conducted on the drug interaction between atorvastatin and colchicine, cases of myopathy, including rhabdomyolysis, have been reported in co-administration of this drug and colchicine, and caution is required when prescribing this drug with colchicine.
23) Gemfibrozil: Due to the increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are used together with gemfibrozil, the combined use of gemfibrozil and this drug should be avoided.
24) Others: In clinical trials, atorvastatin was co-administered with antihypertensive agents and estrogen replacement therapy drugs without clinically significant interactions. Studies on drug interactions with specific drugs have not been conducted.
25) Other fibrate-based drugs: It is known that there is a risk of myopathy when administered in combination with other fibrate-based drugs, so it must be administered with caution.
26) Daptomycin: When daptomycin and HMG-CoA reductase inhibitors are administered together, the risk of myopathy and/or rhabdomyolysis may increase.

7. Administration to pregnant and lactating women
1) Use of this drug during pregnancy is contraindicated. Women of childbearing potential must find an appropriate method of contraception. Use of this medicine should be discontinued when pregnancy is confirmed. Instead, the treatment needs of each individual patient should be considered. This medicine should be administered to women of childbearing age only if there is no possibility of becoming pregnant and after being informed of the potential risk to the fetus. Additionally, treatment for hyperlipidemia is generally not necessary during pregnancy. Atherosclerosis is a chronic process, and discontinuation of lipid-lowering medications during pregnancy has little effect on the long-term treatment outcome of primary hyperlipidemia in most patients.
2) Use of this drug during breastfeeding is contraindicated. In rat studies, atorvastatin and/or its metabolites are present in the milk of lactating rats. If a drug is present in animal milk, it is likely that the drug will also be present in human milk. Statin drugs, including this drug, reduce cholesterol synthesis and may also reduce the synthesis of other cholesterol-derived biologically active substances, and adverse reactions may occur in breast-feeding infants, so women taking atorvastatin should not breast-feed.

8. Administration to children
1) Safety and efficacy over a period of administration of more than 52 weeks in children under 18 years of age have not been studied, and the long-term effects on cardiovascular outcomes are unknown.
2) There is no pharmacokinetic data for pediatric patients.

9. Administration to elderly people
In healthy elderly people over 65 years of age, the plasma concentration of atorvastatin was higher than that in the young adult group (40% increase in Cmax, 30% increase in AUC), but the LDL-cholesterol lowering effect was similar to that in the young adult group.
Elderly age is a risk factor for myopathy and rhabdomyolysis associated with this drug. Dosage selection for elderly patients should be cautious, taking into account the fact that they have a higher incidence of decreased kidney and cardiac function, a higher frequency of underlying disease or other drug treatment, and a higher risk of myopathy. Elderly patients taking the drug should be monitored for an increased risk of myopathy.

10. Administration to patients with renal impairment
Since renal impairment is a risk factor for myopathy and rhabdomyolysis, patients with renal impairment should be monitored for the development of myopathy.

11. Treatment in case of overdose
There is no specific treatment method applicable to atorvastatin overdose. In case of overdose, patients must be treated symptomatically and symptomatic treatment administered if necessary. Liver function tests and serum CK levels should be monitored. Because it is extensively bound to plasma proteins, hemodialysis does not significantly increase the clearance of atorvastatin.

12. Precautions for storage and handling
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause an accident due to misuse of the medicine or cause a decrease in the quality of the medicine, so put it in the original container and keep it tightly closed.

13. Others
1) Carcinogenicity, mutagenicity, fertility: Atorvastatin was not carcinogenic in rat experiments using a dose 63 times the highest human dose (80 mg/day) based on body weight converted to mg per kg, that is, 8 to 16 times higher dose based on AUC value 0-24. The results of a two-year mouse test in which a dose 250 times higher than the highest dose used in humans was administered based on body weight converted to mg per kg showed that in the highest dose group, the incidence of hepatocellular adenoma in males and hepatocellular carcinoma in females increased. Whole body exposure was 6 to 11 times higher based on AUC0-24. All other chemically similar drugs in this class induced tumors in mice and rats at repeated doses of 12 to 125 times the highest recommended clinical dose based on mg/kg of body weight. In four in vitro tests and one in human test, this drug showed no mutagenic potential regardless of its metabolic activity. Atorvastatin was negative in the Ames test using Salmonella typhimurium and Escherichia coli and the in vitro HGPRT forward mutation assay using Chinese hamster lung cells. Atorvastatin did not significantly increase chromosomal abnormalities in the in vitro Chinese hamster lung cell test, and was negative in the in vivo mouse micronucleus test. There were no negative effects on fertility or fertility in male rats administered up to 175 mg/kg/day of atorvastatin or in female rats administered up to 225 mg/kg/day. This dose was 100 to 140 times the highest recommended dose for human use, converted to mg per kg. In a reproductive toxicity test on male rats, when administered at 100 mg/kg/day for 11 weeks, sperm count, sperm motility, and sperm abnormalities increased. When atorvastatin was administered to dogs at doses of 10, 40, and 120 mg/kg for 2 years, there was no negative effect on sperm or semen parameters or histopathology of productive organs.
2) Central nervous system toxicity: It causes optic nerve degeneration (Waller degeneration of retinal geniculate fibers) in a dose-dependent manner in dogs administered drugs that are chemically similar to this class of drugs (approximately 30 times the maximum human dose).
(1) Cerebral hemorrhage was observed in a female dog administered at 120 mg/kg/day (about 16 times the maximum human dose) for 3 months. Cerebral hemorrhage and optic nerve vacuolization were observed after 11 weeks in female dogs administered at an increased dose up to 280 mg/kg/day.
(2) A single tonic convulsion was observed in male dogs (2: 10 mg/kg/day, 120 mg/kg/day) in a 2-year test.
(3) Central nervous system vascular damage (perivascular hemorrhage, edema, and mononuclear cell infiltration in the perivascular space) is also observed in dogs administered other drugs in this class.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 17items

No.Product NameDetailsDate of ChangeDownload
17Atrovan Tab.Precautions for use2026.03.03PDFAtroban Tablet_Change in precautions for use (draft).pdf
16Atrovan Tab.Precautions for use2025.04.08PDFAtrobanjeong_200700764_Change in precautions for use (draft).pdf
15Atrovan Tab.Precautions for use2025.02.11PDF0235_200700764_Change order for precautions for use of Atroban tablet (draft).pdf
14Atrovan Tab.Precautions for use2023.07.08PDF0004_200700764_Precautions for use (Atroban tablet).pdf
13Atrovan Tab.Atroban Tablet (Precautions for use)2019.07.05PDFPrecautions for using Atroban tablets.pdf
12Atrovan Tab.Atroban Tablet (Precautions for use)2018.06.14PDFAtroban tablet.pdf
11Atrovan Tab.Atroban Tablet (Precautions for use)2017.05.24HWPAtorvastatin calcium trihydrate single tablet unification adjustment plan.h
10Atrovan Tab.Atroban Tablet (Precautions for use)2015.11.10HWPAtorvastatin and its salts single tablet system unification adjustment plan.hw
9Atrovan Tab.Atroban Tablet (Precautions for use)2015.01.13HWPAtroban tablet_Precautions for use.hwp
8Atrovan Tab.Atroban Tablet (Precautions for use)2014.01.20HWP)Atorvastatin and its salts single agent (oral) unified adjustment (draft)
7Atrovan Tab.Atroban Tablet (Precautions for use)2013.05.06HWPPermit change order_Atro Banjeong.hwp
6Atrovan Tab.Atroban tablet (ingredient name)2013.01.30HWPAtrobanjeong_Permission changes.hwp
5Atrovan Tab.Atroban tablet (efficacy, dosage, usage, precautions...2012.12.31HWPAtrobanjeong_Permission change order.hwp
4Atrovan Tab.Atroban Tablet (Precautions for use)2010.10.11HWPPrecautions for using Atroban tablets.hwp
3Atrovan Tab.Atroban Tablet (Precautions for use)2009.12.22HWPAtroban tablet (precautions for use) change (2009.12.22).hwp
2Atrovan Tab.Atroban Tablet (Precautions for use)2009.12.07HWPAtroban tablet (precautions for use) change (2009.12.07).hwp
1Atrovan Tab.Atroban Tablet (Precautions for use)2009.10.07HWPAtroban tablet (precautions for use) change (2009.10.07).hwp